@cortneyslosingit's GLP-1 transformation claims fact-checked

What did @cortneyslosingit actually say?

Honestly? Almost nothing. The transcript is basically a dramatic internal monologue that ends with "I Did it" — which in context appears to mean she started a GLP-1 medication after talking herself into it. There is no specific dosage mentioned, no drug named, no health outcome promised. This is more of a vibe than a health claim.

The caption reads "I am so glad I didn't listen," implying she overcame hesitation, likely from people advising her against GLP-1 treatment. That framing is where the implicit claim lives: that the hesitation was wrong and the decision was right. The 315,000 views suggest a lot of people are projecting their own experiences onto a very sparse script. That is not inherently harmful, but it is worth unpacking what message actually travels when a video like this goes wide.

Does the science back this up?

If the underlying message is "GLP-1 medications are worth trying despite social pressure to avoid them," the clinical literature is largely on her side. But the details matter enormously, and those details are completely absent here.

Semaglutide (the active ingredient in Wegovy and Ozempic) demonstrated 14.9% mean body weight reduction over 68 weeks in the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine). Tirzepatide produced even larger reductions, up to 20.9% in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM). Those are real, meaningful outcomes for people with obesity-related health risks. The stigma around these medications is real too. Research published by Rubino et al. (2020, Obesity) documented how weight bias from clinicians and social circles leads patients to delay or avoid effective treatment. So if someone genuinely pushed back on her starting a medically supervised GLP-1 regimen, the discouragement was not automatically good advice.

That said, GLP-1 agonists carry documented side effects including nausea, vomiting, gastroparesis risk, and in rare cases pancreatitis. They require clinical oversight. "I did it" as a content format strips all of that context out.

What did they get wrong (or right)?

She did not technically get anything wrong because she technically said nothing. That is both the defense and the problem. Content creators in the GLP-1 space have a documented influence on treatment-seeking behavior. A 2023 analysis in the Journal of Medical Internet Research (Allem et al.) found that TikTok videos about semaglutide frequently lacked safety information and reached audiences with high engagement. A video framed around "I'm so glad I didn't listen" can function as implicit encouragement for viewers to override their own hesitation, or their doctor's hesitation, without any clinical grounding.

Where she deserves some credit: she did not name a drug, did not claim a cure, did not recommend a dose, and did not promote a product. Compared to a significant portion of GLP-1 content on TikTok, that restraint is notable. The emotional authenticity is also genuinely relatable to people who have faced judgment for pursuing weight-loss treatment. That experience is valid and documented.

What should you actually know?

GLP-1 receptor agonists are not a lifestyle choice you make because a TikTok video resonated. They are prescription medications with real efficacy data and real risk profiles. The decision to start one should involve an evaluation of your metabolic health, cardiovascular risk, thyroid history, and personal medication tolerance. The STEP and SURMOUNT trials showed impressive results in controlled populations with clinical monitoring. Your situation may differ.

Social discouragement of GLP-1 treatment is a real phenomenon driven partly by stigma, partly by misinformation, and partly by legitimate concerns about supply shortages and cost. None of those reasons are the same thing. A friend saying "you don't need that" is not the same as a clinician saying "this is contraindicated for you." Knowing which category of pushback you are dealing with actually matters.

• GLP-1 medications require a prescription and medical supervision in the United States.
• Compounded semaglutide is not equivalent to FDA-approved brand-name drugs. Do not assume otherwise.
• If you are considering a GLP-1 medication, a telehealth evaluation with a licensed provider is an appropriate starting point for assessing eligibility.
• Side effects are common, especially in the first weeks. Nausea affects roughly 44% of semaglutide users in clinical trials (Wilding et al., 2021, NEJM).